Analyst firms · Morgan Stanley · CABA

Morgan Stanley CABA price target and rating history

Cabaletta Bio Inc. (CABA) · Health Care

Morgan Stanley rates Cabaletta Bio Inc. (CABA) Overweight with a $16 price target, as of its latest action on Jan 27, 2023. It has published 4 rating actions on CABA since October 2021, including 1 upgrade and 1 downgrade.

Current rating
Overweight
Price target
$16
Median target, all firms
Too few
Actions on CABA
4

Morgan Stanley price target on CABA

$20$12$320222023202420252026
Morgan Stanley price target on CABA, each point a stated target, October 2021 to January 2023.

Every Morgan Stanley rating on CABA

Questions about Morgan Stanley and CABA

What is Morgan Stanley's price target for CABA?
Morgan Stanley's latest stated price target for Cabaletta Bio Inc. (CABA) is $16, from its action on Jan 27, 2023.
What is Morgan Stanley's rating on CABA?
Morgan Stanley rates CABA Overweight, a bullish rating, as of Jan 27, 2023.
When did Morgan Stanley last change its view on CABA?
On Jan 27, 2023, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $3 to $16.

All Morgan Stanley ratingsCABA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.